Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer
The level of anxiety was examined before treatment by means of the Manifest Anxiety Scale (MAS) in 41 patients with squamous cell carcinoma of the head and neck. They received 5 days of neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU). Granisetron (KYT) was administered daily...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2001-07, Vol.9 (5), p.366-371 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 5 |
| container_start_page | 366 |
| container_title | Supportive care in cancer |
| container_volume | 9 |
| creator | FUJII, Masato OHNO, Yoshihiro TOKUMARU, Yutaka IMANISHI, Yorihisa KANKE, Minoru TOMITA, Toshiki KANZAKI, Jin |
| description | The level of anxiety was examined before treatment by means of the Manifest Anxiety Scale (MAS) in 41 patients with squamous cell carcinoma of the head and neck. They received 5 days of neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU). Granisetron (KYT) was administered daily from day 1 to day 5. Nausea, vomiting, appetite, and well-being were assessed during and after chemotherapy. The relation between the effects of KYT and anxiety was studied. Seventeen patients were proven to have anxiety and were compared with the other 24 patients. In patients with anxiety, the percentage well-being was significantly lower on days 1 and 2 (P=0.008, 0.001). The rate of freedom from nausea was significantly lower from day 4 to day 9 for anxiety patients (P=0.010-0.050). The percentage of anxiety patients without loss of appetite was significantly lower from day 6 to 9 (p=0.001-0.020). The rate of freedom from vomiting was significantly lower on days 4, 5 and 7 for anxiety patients (P=0.024, 0.024, 0.014). The results indicate that the effect of KYT was significantly lower from day 3 to day 7 for anxiety patients (P=0.008-0.045). The anxiety group had significantly poorer well-being at the beginning of chemotherapy, and were not responsive to KYT in the delayed phase. Our results prove that anxiety patients show delayed emesis, and the administration of KYT is considered insufficient. It may be important to co-administer a tranquilizer to any patient who exhibit anxiety as defined by the MAS, in order to reduce delayed emesis. |
| doi_str_mv | 10.1007/s005200000221 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_884107081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2428080841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-e04a9089949630192b22b1bde69b65b1be3b465c098461b0c28c944a86446ff43</originalsourceid><addsrcrecordid>eNpVkMtOwzAQRS0EouWxZIssxDYwjp3EXlYtBaQikKDryHHHNKVNip0A5etxHxLgzYw8x3fkQ8gZgysGkF17gCSG9Yljtke6THAeZZyrfdIFJVgkeJJ0yJH3MwCWZUl8SDqMCZVxxbrk-0FXpUXf0F71VWKzos9Gz5Ha2lH80PNWN2Vd0dpStBZN49ftqwuPPDYuTMqKmiku6maKTi9X9LNsprQ_GDxRXU1oMhxvoqaoJ5uLCs0bNboy6E7IgdVzj6e7ekzGw5uX_l00ery97_dGkeEiaSIEoRVIpYRKOTAVF3FcsGKCqSrSJHTIC5EmBpQUKSvAxNIoIbRMhUitFfyYXGxzl65-b8NX81nduiqszKUUDDKQLEDRFjKu9t6hzZeuXGi3yhnka9H5P9GBP9-FtsUCJ7_0zmwALneA9sGoDcpM6f-kSs5SyX8Aa5eDWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>884107081</pqid></control><display><type>article</type><title>Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>FUJII, Masato ; OHNO, Yoshihiro ; TOKUMARU, Yutaka ; IMANISHI, Yorihisa ; KANKE, Minoru ; TOMITA, Toshiki ; KANZAKI, Jin</creator><creatorcontrib>FUJII, Masato ; OHNO, Yoshihiro ; TOKUMARU, Yutaka ; IMANISHI, Yorihisa ; KANKE, Minoru ; TOMITA, Toshiki ; KANZAKI, Jin</creatorcontrib><description>The level of anxiety was examined before treatment by means of the Manifest Anxiety Scale (MAS) in 41 patients with squamous cell carcinoma of the head and neck. They received 5 days of neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU). Granisetron (KYT) was administered daily from day 1 to day 5. Nausea, vomiting, appetite, and well-being were assessed during and after chemotherapy. The relation between the effects of KYT and anxiety was studied. Seventeen patients were proven to have anxiety and were compared with the other 24 patients. In patients with anxiety, the percentage well-being was significantly lower on days 1 and 2 (P=0.008, 0.001). The rate of freedom from nausea was significantly lower from day 4 to day 9 for anxiety patients (P=0.010-0.050). The percentage of anxiety patients without loss of appetite was significantly lower from day 6 to 9 (p=0.001-0.020). The rate of freedom from vomiting was significantly lower on days 4, 5 and 7 for anxiety patients (P=0.024, 0.024, 0.014). The results indicate that the effect of KYT was significantly lower from day 3 to day 7 for anxiety patients (P=0.008-0.045). The anxiety group had significantly poorer well-being at the beginning of chemotherapy, and were not responsive to KYT in the delayed phase. Our results prove that anxiety patients show delayed emesis, and the administration of KYT is considered insufficient. It may be important to co-administer a tranquilizer to any patient who exhibit anxiety as defined by the MAS, in order to reduce delayed emesis.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s005200000221</identifier><identifier>PMID: 11497391</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject><![CDATA[Adult ; Aged ; Antiemetics - administration & dosage ; Antiemetics - therapeutic use ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Anxiety ; Anxiety - psychology ; Biological and medical sciences ; Carcinoma, Squamous Cell - drug therapy ; Chemotherapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Drug Administration Schedule ; Drug toxicity and drugs side effects treatment ; Evaluation Studies as Topic ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Granisetron - administration & dosage ; Granisetron - therapeutic use ; Head & neck cancer ; Head and Neck Neoplasms - drug therapy ; Humans ; Male ; Manifest Anxiety Scale - standards ; Medical sciences ; Middle Aged ; Nausea - chemically induced ; Nausea - prevention & control ; Pharmacology. Drug treatments ; Toxicity: digestive system ; Vomiting - chemically induced ; Vomiting - prevention & control]]></subject><ispartof>Supportive care in cancer, 2001-07, Vol.9 (5), p.366-371</ispartof><rights>2001 INIST-CNRS</rights><rights>Springer-Verlag 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-e04a9089949630192b22b1bde69b65b1be3b465c098461b0c28c944a86446ff43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1083168$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11497391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUJII, Masato</creatorcontrib><creatorcontrib>OHNO, Yoshihiro</creatorcontrib><creatorcontrib>TOKUMARU, Yutaka</creatorcontrib><creatorcontrib>IMANISHI, Yorihisa</creatorcontrib><creatorcontrib>KANKE, Minoru</creatorcontrib><creatorcontrib>TOMITA, Toshiki</creatorcontrib><creatorcontrib>KANZAKI, Jin</creatorcontrib><title>Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><description>The level of anxiety was examined before treatment by means of the Manifest Anxiety Scale (MAS) in 41 patients with squamous cell carcinoma of the head and neck. They received 5 days of neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU). Granisetron (KYT) was administered daily from day 1 to day 5. Nausea, vomiting, appetite, and well-being were assessed during and after chemotherapy. The relation between the effects of KYT and anxiety was studied. Seventeen patients were proven to have anxiety and were compared with the other 24 patients. In patients with anxiety, the percentage well-being was significantly lower on days 1 and 2 (P=0.008, 0.001). The rate of freedom from nausea was significantly lower from day 4 to day 9 for anxiety patients (P=0.010-0.050). The percentage of anxiety patients without loss of appetite was significantly lower from day 6 to 9 (p=0.001-0.020). The rate of freedom from vomiting was significantly lower on days 4, 5 and 7 for anxiety patients (P=0.024, 0.024, 0.014). The results indicate that the effect of KYT was significantly lower from day 3 to day 7 for anxiety patients (P=0.008-0.045). The anxiety group had significantly poorer well-being at the beginning of chemotherapy, and were not responsive to KYT in the delayed phase. Our results prove that anxiety patients show delayed emesis, and the administration of KYT is considered insufficient. It may be important to co-administer a tranquilizer to any patient who exhibit anxiety as defined by the MAS, in order to reduce delayed emesis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiemetics - administration & dosage</subject><subject>Antiemetics - therapeutic use</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Anxiety</subject><subject>Anxiety - psychology</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Granisetron - administration & dosage</subject><subject>Granisetron - therapeutic use</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Manifest Anxiety Scale - standards</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nausea - chemically induced</subject><subject>Nausea - prevention & control</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: digestive system</subject><subject>Vomiting - chemically induced</subject><subject>Vomiting - prevention & control</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVkMtOwzAQRS0EouWxZIssxDYwjp3EXlYtBaQikKDryHHHNKVNip0A5etxHxLgzYw8x3fkQ8gZgysGkF17gCSG9Yljtke6THAeZZyrfdIFJVgkeJJ0yJH3MwCWZUl8SDqMCZVxxbrk-0FXpUXf0F71VWKzos9Gz5Ha2lH80PNWN2Vd0dpStBZN49ftqwuPPDYuTMqKmiku6maKTi9X9LNsprQ_GDxRXU1oMhxvoqaoJ5uLCs0bNboy6E7IgdVzj6e7ekzGw5uX_l00ery97_dGkeEiaSIEoRVIpYRKOTAVF3FcsGKCqSrSJHTIC5EmBpQUKSvAxNIoIbRMhUitFfyYXGxzl65-b8NX81nduiqszKUUDDKQLEDRFjKu9t6hzZeuXGi3yhnka9H5P9GBP9-FtsUCJ7_0zmwALneA9sGoDcpM6f-kSs5SyX8Aa5eDWw</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>FUJII, Masato</creator><creator>OHNO, Yoshihiro</creator><creator>TOKUMARU, Yutaka</creator><creator>IMANISHI, Yorihisa</creator><creator>KANKE, Minoru</creator><creator>TOMITA, Toshiki</creator><creator>KANZAKI, Jin</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20010701</creationdate><title>Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer</title><author>FUJII, Masato ; OHNO, Yoshihiro ; TOKUMARU, Yutaka ; IMANISHI, Yorihisa ; KANKE, Minoru ; TOMITA, Toshiki ; KANZAKI, Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-e04a9089949630192b22b1bde69b65b1be3b465c098461b0c28c944a86446ff43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiemetics - administration & dosage</topic><topic>Antiemetics - therapeutic use</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Anxiety</topic><topic>Anxiety - psychology</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Granisetron - administration & dosage</topic><topic>Granisetron - therapeutic use</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Manifest Anxiety Scale - standards</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nausea - chemically induced</topic><topic>Nausea - prevention & control</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: digestive system</topic><topic>Vomiting - chemically induced</topic><topic>Vomiting - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUJII, Masato</creatorcontrib><creatorcontrib>OHNO, Yoshihiro</creatorcontrib><creatorcontrib>TOKUMARU, Yutaka</creatorcontrib><creatorcontrib>IMANISHI, Yorihisa</creatorcontrib><creatorcontrib>KANKE, Minoru</creatorcontrib><creatorcontrib>TOMITA, Toshiki</creatorcontrib><creatorcontrib>KANZAKI, Jin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUJII, Masato</au><au>OHNO, Yoshihiro</au><au>TOKUMARU, Yutaka</au><au>IMANISHI, Yorihisa</au><au>KANKE, Minoru</au><au>TOMITA, Toshiki</au><au>KANZAKI, Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer</atitle><jtitle>Supportive care in cancer</jtitle><addtitle>Support Care Cancer</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>9</volume><issue>5</issue><spage>366</spage><epage>371</epage><pages>366-371</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>The level of anxiety was examined before treatment by means of the Manifest Anxiety Scale (MAS) in 41 patients with squamous cell carcinoma of the head and neck. They received 5 days of neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU). Granisetron (KYT) was administered daily from day 1 to day 5. Nausea, vomiting, appetite, and well-being were assessed during and after chemotherapy. The relation between the effects of KYT and anxiety was studied. Seventeen patients were proven to have anxiety and were compared with the other 24 patients. In patients with anxiety, the percentage well-being was significantly lower on days 1 and 2 (P=0.008, 0.001). The rate of freedom from nausea was significantly lower from day 4 to day 9 for anxiety patients (P=0.010-0.050). The percentage of anxiety patients without loss of appetite was significantly lower from day 6 to 9 (p=0.001-0.020). The rate of freedom from vomiting was significantly lower on days 4, 5 and 7 for anxiety patients (P=0.024, 0.024, 0.014). The results indicate that the effect of KYT was significantly lower from day 3 to day 7 for anxiety patients (P=0.008-0.045). The anxiety group had significantly poorer well-being at the beginning of chemotherapy, and were not responsive to KYT in the delayed phase. Our results prove that anxiety patients show delayed emesis, and the administration of KYT is considered insufficient. It may be important to co-administer a tranquilizer to any patient who exhibit anxiety as defined by the MAS, in order to reduce delayed emesis.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>11497391</pmid><doi>10.1007/s005200000221</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2001-07, Vol.9 (5), p.366-371 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_journals_884107081 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Antiemetics - administration & dosage Antiemetics - therapeutic use Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Anxiety Anxiety - psychology Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Chemotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Drug Administration Schedule Drug toxicity and drugs side effects treatment Evaluation Studies as Topic Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Granisetron - administration & dosage Granisetron - therapeutic use Head & neck cancer Head and Neck Neoplasms - drug therapy Humans Male Manifest Anxiety Scale - standards Medical sciences Middle Aged Nausea - chemically induced Nausea - prevention & control Pharmacology. Drug treatments Toxicity: digestive system Vomiting - chemically induced Vomiting - prevention & control |
| title | Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A49%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Manifest%20Anxiety%20Scale%20for%20evaluation%20of%20effects%20of%20granisetron%20in%20chemotherapy%20with%20CDDP%20and%205FU%20for%20head%20and%20neck%20cancer&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=FUJII,%20Masato&rft.date=2001-07-01&rft.volume=9&rft.issue=5&rft.spage=366&rft.epage=371&rft.pages=366-371&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s005200000221&rft_dat=%3Cproquest_cross%3E2428080841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=884107081&rft_id=info:pmid/11497391&rfr_iscdi=true |